DE60045082D1 - Behandlung von überaktivität glatter muskulatur mit (r)-oxybutynin und (r)-desethyloxybutynin - Google Patents
Behandlung von überaktivität glatter muskulatur mit (r)-oxybutynin und (r)-desethyloxybutyninInfo
- Publication number
- DE60045082D1 DE60045082D1 DE60045082T DE60045082T DE60045082D1 DE 60045082 D1 DE60045082 D1 DE 60045082D1 DE 60045082 T DE60045082 T DE 60045082T DE 60045082 T DE60045082 T DE 60045082T DE 60045082 D1 DE60045082 D1 DE 60045082D1
- Authority
- DE
- Germany
- Prior art keywords
- oxybutynin
- desethyloxybutynin
- smooth muscle
- optically pure
- musculatory
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- XIQVNETUBQGFHX-QFIPXVFZSA-N (R)-oxybutynin Chemical compound C1([C@](O)(C(=O)OCC#CCN(CC)CC)C=2C=CC=CC=2)CCCCC1 XIQVNETUBQGFHX-QFIPXVFZSA-N 0.000 title 1
- 206010037211 Psychomotor hyperactivity Diseases 0.000 title 1
- XIQVNETUBQGFHX-UHFFFAOYSA-N Ditropan Chemical compound C=1C=CC=CC=1C(O)(C(=O)OCC#CCN(CC)CC)C1CCCCC1 XIQVNETUBQGFHX-UHFFFAOYSA-N 0.000 abstract 3
- SNIBJKHIKIIGPR-UHFFFAOYSA-N N-desethyloxybutynin Chemical compound C=1C=CC=CC=1C(O)(C(=O)OCC#CCNCC)C1CCCCC1 SNIBJKHIKIIGPR-UHFFFAOYSA-N 0.000 abstract 3
- 208000013403 hyperactivity Diseases 0.000 abstract 3
- 229960005434 oxybutynin Drugs 0.000 abstract 3
- 210000002460 smooth muscle Anatomy 0.000 abstract 3
- 206010046543 Urinary incontinence Diseases 0.000 abstract 1
- 230000001078 anti-cholinergic effect Effects 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 230000002496 gastric effect Effects 0.000 abstract 1
- 208000002551 irritable bowel syndrome Diseases 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 230000003389 potentiating effect Effects 0.000 abstract 1
- 230000002048 spasmolytic effect Effects 0.000 abstract 1
- 208000024891 symptom Diseases 0.000 abstract 1
- 210000003932 urinary bladder Anatomy 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Urology & Nephrology (AREA)
- Virology (AREA)
- Pulmonology (AREA)
- Communicable Diseases (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Oncology (AREA)
- Emergency Medicine (AREA)
- Epidemiology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/US2000/015515 WO2001093683A1 (en) | 2000-06-07 | 2000-06-07 | Treating smooth muscle hyperactivity with (r)-oxybutynin and (r)- desethyloxybutynin |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DE60045082D1 true DE60045082D1 (de) | 2010-11-18 |
Family
ID=21741461
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE60045082T Expired - Lifetime DE60045082D1 (de) | 2000-06-07 | 2000-06-07 | Behandlung von überaktivität glatter muskulatur mit (r)-oxybutynin und (r)-desethyloxybutynin |
Country Status (9)
| Country | Link |
|---|---|
| EP (1) | EP1286591B1 (https=) |
| JP (1) | JP5684964B2 (https=) |
| CN (3) | CN1454054A (https=) |
| AT (1) | ATE483459T1 (https=) |
| AU (2) | AU2000255966B2 (https=) |
| CA (1) | CA2378754A1 (https=) |
| DE (1) | DE60045082D1 (https=) |
| ES (1) | ES2350330T3 (https=) |
| WO (1) | WO2001093683A1 (https=) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2005516992A (ja) * | 2001-12-21 | 2005-06-09 | ブリッジ ファーマ、インコーポレイテッド | オキシブチニンの非心律動異常惹起性代謝物 |
| EP1424079A1 (en) * | 2002-11-27 | 2004-06-02 | Boehringer Ingelheim International GmbH | Combination of a beta-3-receptor agonist and of a reuptake inhibitor of serotonin and/or norepinephrine |
| ATE361101T1 (de) * | 2004-08-24 | 2007-05-15 | Nutricia Nv | Nahrungszusammensetzung die unverdauliche oligosaccharide enthält |
| US8920392B2 (en) | 2009-05-05 | 2014-12-30 | Watson Laboratories, Inc. | Method for treating overactive bladders and a device for storage and administration of topical oxybutynin compositions |
| EP2680859B1 (en) | 2011-03-02 | 2022-04-27 | Jerome Schentag | Compositions, methods of treatment and diagnostics for treatment of hepatic steatosis alone or in combination with a hepatitis c virus infection |
| US10532045B2 (en) | 2013-12-18 | 2020-01-14 | Signpath Pharma, Inc. | Liposomal mitigation of drug-induced inhibition of the cardiac IKr channel |
| US10449193B2 (en) | 2011-06-03 | 2019-10-22 | Signpath Pharma Inc. | Protective effect of DMPC, DMPG, DMPC/DMPG, lysoPG and lysoPC against drugs that cause channelopathies |
| US8753674B2 (en) | 2011-06-03 | 2014-06-17 | Signpath Pharma Inc. | Liposomal mitigation of drug-induced long QT syndrome and potassium delayed-rectifier current |
| US10238602B2 (en) | 2011-06-03 | 2019-03-26 | Signpath Pharma, Inc. | Protective effect of DMPC, DMPG, DMPC/DMPG, LysoPG and LysoPC against drugs that cause channelopathies |
| US10349884B2 (en) | 2011-06-03 | 2019-07-16 | Sighpath Pharma Inc. | Liposomal mitigation of drug-induced inhibition of the cardiac ikr channel |
| US12004868B2 (en) | 2011-06-03 | 2024-06-11 | Signpath Pharma Inc. | Liposomal mitigation of drug-induced inhibition of the cardiac IKr channel |
| US10117881B2 (en) | 2011-06-03 | 2018-11-06 | Signpath Pharma, Inc. | Protective effect of DMPC, DMPG, DMPC/DMPG, LYSOPG and LYSOPC against drugs that cause channelopathies |
| US20140135392A1 (en) * | 2012-11-13 | 2014-05-15 | NeuRx Pharmaceuticals LLC | Methods for the treatment of sialorrhea |
| US20160151321A1 (en) | 2012-11-13 | 2016-06-02 | Dinesh C. Patel | Methods for the treatment of sialorrhea |
| CN103169660B (zh) * | 2013-04-15 | 2015-04-08 | 石正国 | 一种制备高包封率的利巴韦林脂质体口服乳 |
| AU2015269699B2 (en) | 2014-06-03 | 2020-08-13 | Avanti Polar Lipids, Inc. | Protective effect of DMPC, DMPG, DMPC/DMPG, EGPG, LysoPG and LysoPC against drugs that cause channelopathies |
| AU2017257496B2 (en) | 2016-04-27 | 2020-05-07 | Signpath Pharma, Inc. | Prevention of drug-induced atrio-ventricular block |
| JP7776442B2 (ja) * | 2020-05-05 | 2025-11-26 | アプニメッド，インコーポレイテッド（デラウェア） | （ｒ）－オキシブチニン塩酸塩の多形形態 |
| TW202207952A (zh) * | 2020-07-03 | 2022-03-01 | 愛爾蘭商普候克斯根有限公司 | 病毒感染 |
| CN117396460A (zh) * | 2021-05-04 | 2024-01-12 | 爱普宁公司(特拉华) | (r)-奥昔布宁d-苹果酸盐的固体形式 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4008269A (en) * | 1970-05-05 | 1977-02-15 | William H. Rorer, Inc. | Phenylacetic acids |
| IT1231237B (it) * | 1987-09-21 | 1991-11-26 | Angeli Inst Spa | Derivati eterociclici |
| US5677346A (en) * | 1995-01-31 | 1997-10-14 | Sepracor, Inc. | Treating urinary incontinence using (S)-desethyloxybutynin |
| US5973182A (en) * | 1998-10-22 | 1999-10-26 | Sepracor Inc. | Carbonate Intermediates useful in the preparation of optically active cyclohexylphenylglycolate esters |
-
2000
- 2000-06-07 JP JP2002501260A patent/JP5684964B2/ja not_active Expired - Fee Related
- 2000-06-07 AU AU2000255966A patent/AU2000255966B2/en not_active Expired
- 2000-06-07 ES ES00941235T patent/ES2350330T3/es not_active Expired - Lifetime
- 2000-06-07 AU AU5596600A patent/AU5596600A/xx active Pending
- 2000-06-07 CN CN00819623A patent/CN1454054A/zh active Pending
- 2000-06-07 CA CA002378754A patent/CA2378754A1/en not_active Abandoned
- 2000-06-07 WO PCT/US2000/015515 patent/WO2001093683A1/en not_active Ceased
- 2000-06-07 AT AT00941235T patent/ATE483459T1/de not_active IP Right Cessation
- 2000-06-07 CN CNA2007101418683A patent/CN101108176A/zh active Pending
- 2000-06-07 EP EP00941235A patent/EP1286591B1/en not_active Expired - Lifetime
- 2000-06-07 DE DE60045082T patent/DE60045082D1/de not_active Expired - Lifetime
-
2003
- 2003-05-16 CN CN03131438A patent/CN1451388A/zh active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP1286591A4 (en) | 2007-04-04 |
| JP5684964B2 (ja) | 2015-03-18 |
| CN1454054A (zh) | 2003-11-05 |
| AU2000255966B2 (en) | 2005-03-24 |
| JP2003535110A (ja) | 2003-11-25 |
| WO2001093683A1 (en) | 2001-12-13 |
| AU2000255966A1 (en) | 2002-03-07 |
| CA2378754A1 (en) | 2001-12-13 |
| EP1286591A1 (en) | 2003-03-05 |
| ES2350330T3 (es) | 2011-01-21 |
| CN1451388A (zh) | 2003-10-29 |
| EP1286591B1 (en) | 2010-10-06 |
| ATE483459T1 (de) | 2010-10-15 |
| CN101108176A (zh) | 2008-01-23 |
| AU5596600A (en) | 2001-12-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE60045082D1 (de) | Behandlung von überaktivität glatter muskulatur mit (r)-oxybutynin und (r)-desethyloxybutynin | |
| CY1119029T1 (el) | Θεραπευτικη αντιμετωπιση συμπαγων εγκεφαλικων νεοπλασιων με ενα παραγωγο ραπαμυκινης | |
| ATE292971T1 (de) | (s,s)-reboxetin zur behandlung von peripheren neuropathien | |
| CA2451474A1 (en) | Triamide-substituted indoles, benzofuranes and benzothiophenes as inhibitors of microsomal triglyceride transfer protein (mtp) and/or apolipoprotein b (apo b) secretion | |
| DE60027769D1 (de) | Pyrrolidin-derivate als inhibitoren von cyclischer amp-phosphodiesterase | |
| DK1202736T3 (da) | Nikotin i terapeutisk angiogenese og vasculogenese | |
| EA200700116A1 (ru) | Четвертичные соли, антагонисты ccr2 | |
| MXPA03000809A (es) | Polimero de polisiloxano, procedimiento para su preparacion y su uso. | |
| DK0927024T3 (da) | Indretning og fremgangsmåde til behandling af öjensygdomme | |
| DK1155019T3 (da) | Substituerede porphyriner og deres terapeutiske anvendelse | |
| WO2002103103A3 (en) | Fluorine-containing compounds and polymers derived therefrom | |
| NO20054296D0 (no) | Anvendelse av palonosetron for behandling av kvalme og oppkast etter kirurgisk inngrep | |
| NO306779B1 (no) | Naftalamider, anvendelse derav og farmasöytisk preparat | |
| DK0786991T3 (da) | Polyaminforbindelsre til behandling af proliferative karsygdomme | |
| ATE197762T1 (de) | Verwendung von optisch reines (+) norcisapride zur behandlung von erbrechen und zns-störungen | |
| DE60014136D1 (de) | Sapogenin derivate zur behandlung von kognitiven störungen | |
| BRPI0506970B8 (pt) | derivados de alfa-aminoamida úteis no tratamento de distúrbios do trato urinário inferior | |
| IL152450A (en) | Compounds and compositions for use in treating tnf-?? mediated conditions | |
| FR2872508B1 (fr) | Composition de traitement d'un verre pour en ameliorer la resistance mecanique par guerison des defauts de surface, procedes de traitement correspondants et verres traites obtenus | |
| WO2003092611A3 (en) | Methods of inducing formation of functional and organized lymphatic vessels | |
| EP1152760A4 (en) | USE OF 4-AMINOPYRIDINE FOR THE TREATMENT OF PERIPHERAL NEUROPATHIES | |
| NO20042138L (no) | Forbindelser og fremgangsmate for behandling av hyperaktiv blaere | |
| NZ511997A (en) | Isonipecotamides for the treatment of integrin-mediated disorders | |
| EP1233075A3 (en) | BDNF polymorphism and association with bipolar disorder | |
| WO2001011085A3 (en) | Bdnf polymorphism and association with bipolar disorder |